Related Experiment Video
Updated: Jun 14, 2025
06:24
Author Spotlight: Advancements in iPSCs and Genetic Disease Research
Published on: October 20, 2023
1.0K
Pretreatment can alleviate programmed cell death in mesenchymal stem cells
Xin-Xing Wan1, Xi-Min Hu2, Qi Zhang3
1Department of Endocrinology, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan Province, China.
World Journal of Stem Cells
|September 2, 2024
Summary
Ferroptosis, a form of cell death, significantly reduces mesenchymal stem cell (MSC) viability after transplantation. Preconditioning MSCs to control ferroptosis could enhance cell survival and improve cell-based therapy outcomes.
Area of Science:
- Biomedical Engineering
- Cell Biology
- Regenerative Medicine
Background:
- Mesenchymal stem cells (MSCs) are crucial for cell-based therapies.
- Ferroptosis, a regulated form of cell death, negatively impacts MSC viability post-engraftment.
- Reduced MSC viability compromises the therapeutic efficacy of cell-based treatments.
Discussion:
- The editorial examines the role of ferroptosis in MSC survival and therapeutic potential.
- It highlights the potential of cellular preconditioning to modulate ferroptosis pathways.
- Manipulating ferroptosis may overcome a key barrier in MSC-based regenerative medicine.
Key Insights:
- Ferroptosis is a major cause of donor MSC loss after transplantation.
- Targeting ferroptosis pathways offers a novel strategy to enhance MSC survival.
- Cellular preconditioning can be explored to improve MSC engraftment and function.
Outlook:
- Further research is needed to elucidate the precise mechanisms of ferroptosis in MSCs.
- Developing effective preconditioning strategies is essential for advancing MSC therapies.
- Understanding the interplay between cell death and MSC therapeutic outcomes is critical for clinical translation.
